On May 30, 2009, Allos Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release reporting updated data from the Company's pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 and attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

(d) Exhibits.

99.1     Press Release, dated May 30, 2009, entitled "Allos Therapeutics Reports
         Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at
         45th ASCO Annual Meeting."